Contact us
Appointment
Appointment

BMS (Bristol Myers Squibb) CN012-0024 Alzheimer’s Disease (AD)

If you or someone you care for is experiencing agitation related to Alzheimer’s disease, the ADAGIO-2 Study may be an opportunity to learn more about a potential treatment option.

ADAGIO-2 Study for Agitation in
Alzheimer’s Disease

Agitation is a common and challenging symptom of Alzheimer’s disease. It may include restlessness, irritability, emotional distress, or aggressive behaviors, and can significantly affect daily life for both individuals living with Alzheimer’s and their caregivers. This clinical research study is designed to better understand and evaluate treatment options for agitation associated with Alzheimer’s disease.

Frequently Asked Questions

Who May Be Eligible to Participate?

Participants may qualify if they:
  • Are between 55 and 90 years of age
  • Have a diagnosis of Alzheimer’s disease
  • Have experienced physical and/or verbal agitation for at least 2 weeks, such as:
  • Restlessness or pacing
  • Shouting, cursing, or verbal outbursts
  • Resistance to care
  • Wandering or throwing objects
Additional eligibility criteria will be reviewed with you by the study team.

Agitation is a common symptom of Alzheimer’s disease and may include restlessness, irritability, pacing, verbal outbursts, resistance to care, or aggressive behavior. These symptoms can be distressing for both the individual and their caregivers.

Agitation can greatly affect quality of life and increase caregiver stress. Clinical studies like ADAGIO-2 help researchers evaluate potential treatments aimed at reducing agitation and improving daily functioning and comfort.

Participants receive study-related care from a specialized medical research team. Caregivers are supported throughout the process, and the study team will explain all visits, evaluations, and requirements in detail before participation begins.

Accessibility Toolbar